© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
Treatment with Tecentriq plus Avastin or with Keytruda alone delays disease progression and improves survival.
The immunotherapy and targeted therapy combo improved both overall survival and patient-reported outcomes.
Tecentriq plus Avastin improved improved overall survival and patient experiences during treatment.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
